Company Long-Term Loans and Borrowings: Harrow Health (HROW)

Public company logo of Harrow Inc (HROW)

This chart illustrates the market value of Harrow, Inc. (HROW), which is accompanied by the 0.28 indicator. The business relies on a network of ophthalmology centers, offering treatments for corneal dryness. Growth is driven by strong sales of Vevye and Iheezo, as well as the integration of Novartis assets, which has improved profitability. Current success is based on the sale of premium drops and the expansion of clinic coverage.

HROW Harrow, Inc. Company Long-Term Debts (07/04/2022 - 10/29/2026)

Harrow Health (HROW) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price harrowinc.com|HROW - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Harrow|HROW - Total Company Value
- book capitalization information:
Accounting Value per Share Harrow|HROW - Book Capitalization|Market Capitalization to Book Value Ratio harrowinc.com|HROW - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Harrow, Inc.|HROW - Long-Term Debt to Capital|Current Liabilities to Capital Harrow Corp|HROW - Company Total Debt|Debts to Book Value Harrow|HROW - Company Long-Term Debts|Short-Term Debt Harrow
Fundamental company valuation:Harrow, Inc.
Brand item of Harrow

When screening business quality, investors assess capital stability by analyzing liabilities with maturities exceeding one year. This indicator measures the total volume of long-term loans, which, given the inelastic demand for Harrow, Inc. (HROW) ophthalmic drugs, allows for a comparison of stable cash flow against debt service costs to evaluate the deleveraging risk of the business's long-term debt.

Who Harrow, Inc. competes with

Company Long-Term Debts alcon.com ALC|BLCO - Company Long-Term Debt|Company Long-Term Loans and Borrowings GKOS (Glaukos Corp)|Apellis Pharmaceuticals Inc (APLS) - Company Long-Term Debt|Company Long-Term Liabilities Belite Bio, Inc.|OCUL (Ocular Therapeutix) - Company Long-Term Debts|Company Long-Term Debts viridiantherapeutics.com|Company Long-Term Liabilities LENZ (LENZ Therapeutics)|OCS (Oaktree Specialty Lending) - Company Long-Term Loans and Borrowings|Company Long-Term Debts EYPT (EyePoint Pharma)|Kodiak Corp (KOD) - Long-Term Debt|ALDX: Company Long-Term Liabilities|Long-Term Debt KALA BIO, Inc.|IRD: Company Long-Term Debts|Long-Term Debt OKYO Pharma (OKYO)|Company Long-Term Debt Adverum Biotechnologies Inc.|Outlook Therapeutics Corp (OTLK) - Long-Term Debt Volume|Company Long-Term Debts CLSD|NBY (novabay.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts KPRX (Kiora Pharmaceuticals, Inc.)|Company Long-Term Debts Alimera Sciences Inc ALIM|EYEN - Company Long-Term Debt|Company Long-Term Loans and Borrowings GHSI (Guardion Health)|Ocuphire Pharma, Inc. (OCUP) - Company Long-Term Debt|opthea.com - Company Long-Term Loans and Borrowings